Therapeutic effects of chemotherapy combined with pertuzumab and trastuzumab in neoadjuvant treatment of early breast cancer

doi:10.3877/cma.j.issn.1674-0785.2020.05.005

Abstract

Abstract:

Objective

To investigate the clinical effects of docetaxel (T)+ carboplatin (C) combined with trastuzumab (H)+ pertuzumab (P) in the treatment of human epidermal growth factor receptor-2 (HER-2) positive early breast cancer.

Methods

From March 2019 to December 2019, the clinical data of HER-2 positive breast cancer patients who received new adjuvant treatment of TCHP and underwent surgery at the Breast Disease Center of Peking University First Hospital were analyzed retrospectively. During the neoadjuvant treatment, magnetic resonance imaging was used to evaluate the clinical effects, and the Miler-Payne grading system was used to evaluate the postoperative pathology. The clinical effects of TCHP in HER-2 positive breast cancer patients were analyzed.

Results

A total of 10 HER-2 positive patients were enrolled in this study. All of them were female, with a median age of 48 years old. There were nine cases who received TCHP treatment initially, and one case was switched to the TCHP regimen after the first cycle of TCH treatment. The pathologic complete response rate was 80% (8/10).

Conclusion

TCHP is an effective new adjuvant therapy for HER-2 positive breast cancer patients, with controllable side effects.

Key words: Breast neoplasms, Receptor, epidermal growth factor, Targeted therapy, Pertuzumab

Yuanjia Cheng, Ling Xu, Jingming Ye, Hong Zhang, Shuang Zhang, Yinhua Liu, Zonghan Li. Therapeutic effects of chemotherapy combined with pertuzumab and trastuzumab in neoadjuvant treatment of early breast cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(05): 344-348.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2020.05.005

https://zhlcyszz.cma-cmc.com.cn/EN/Y2020/V14/I05/344

Figures/Tables 2

References 16

1	Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Clin Oncol, 2010, 28(16): 2784-2795.
2	Wolff AC, Hammond M, Allison KH, et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary [J]. J Oncol Pract, 2018, 14(7): 437-441.
3	Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
4	Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J]. Breast, 2003, 12(5): 320-327.
5	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(1): 7-34.
6	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
7	Network NCC. Breast Cancer [M]. Version 3ed. America, National Comprehensive Cancer Network® (NCCN®), 2019: 57
8	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2019 [M]. 北京：人民卫生出版社, 2019.
9	徐玲，叶京明，朱赛楠, 等. HER-2阳性早期乳腺癌TCH方案新辅助治疗疗效分析[J].中华医学杂志, 2018, 98(12): 907-911.
10	Ling X, Jingming Y, Sainan Z, et al. Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in HER-2-positive breast cancer [J]. Natl Med J China, 2018, 98(12): 907-911.
11	Escrivá-de-Romaní S, Arumí M, Bellet M, et al. HER2-positive breast cancer: Current and new therapeutic strategies [J]. Breast, 2018, 39: 80-88.
12	Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2012, 13(1): 25-32.
13	Shao Z, Pang D, Yang H, et al. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial [J]. JAMA Oncol, 2019. DOI: 10.1001/jamaoncol.2019.3692.
14	Chen S, Liang Y, Feng Z, et al. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis [J]. BMC Cancer, 2019, 19(1): 973.
15	Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) [J]. Ann Oncol, 2013, 24(9): 2278-2284.
16	Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study [J]. J Clin Oncol, 2019, 37(25): 2206-2216.

项目		例数	百分比（%）
年龄（岁）		?	?
?	<30	1	10.0
?	30~<40	1	10.0
?	40~<50	4	40.0
?	50~<60	2	20.0
?	60~<70	2	20.0
月经状态		?	?
?	绝经前	6	60.0
?	绝经后	4	40.0
肿瘤分期		?	?
?	T1	1	10.0
?	T2	7	70.0
?	T3	2	20.0
淋巴结状态		?	?
?	N0	2	20.0
?	N1+N1mi	6	60.0
?	N2	2	20.0
?	N3	0	0.0
分子分型		?	?
?	Luminal B（HER-2阳性）型	4	40.0
?	HER-2阳性型	6	60.0
组织学分级		?	?
?	G1	0	0
?	G2	4	40.0
?	G3	6	60.0

项目		例数	百分比（%）
年龄（岁）		?	?
?	<30	1	10.0
?	30~<40	1	10.0
?	40~<50	4	40.0
?	50~<60	2	20.0
?	60~<70	2	20.0
月经状态		?	?
?	绝经前	6	60.0
?	绝经后	4	40.0
肿瘤分期		?	?
?	T1	1	10.0
?	T2	7	70.0
?	T3	2	20.0
淋巴结状态		?	?
?	N0	2	20.0
?	N1+N1mi	6	60.0
?	N2	2	20.0
?	N3	0	0.0
分子分型		?	?
?	Luminal B（HER-2阳性）型	4	40.0
?	HER-2阳性型	6	60.0
组织学分级		?	?
?	G1	0	0
?	G2	4	40.0
?	G3	6	60.0

不良反应	1级（例）	2级（例）	3级（例）	百分比（%）
恶心	4	1	1	60
呕吐	4	0	1	50
厌食	2	1	1	40
味觉改变	5	1	0	60
视力下降	1	0	0	10
失眠	4	0	0	40
疲劳乏力	8	1	0	90
肌痛	3	1	0	40
骨痛	4	1	0	50
腹泻	5	3	0	80
便秘	3	2	0	50
口腔溃疡	1	0	0	10
手足麻木	1	2	0	30
心悸	1	0	0	10
骨髓抑制	0	2	1	30

不良反应	1级（例）	2级（例）	3级（例）	百分比（%）
恶心	4	1	1	60
呕吐	4	0	1	50
厌食	2	1	1	40
味觉改变	5	1	0	60
视力下降	1	0	0	10
失眠	4	0	0	40
疲劳乏力	8	1	0	90
肌痛	3	1	0	40
骨痛	4	1	0	50
腹泻	5	3	0	80
便秘	3	2	0	50
口腔溃疡	1	0	0	10
手足麻木	1	2	0	30
心悸	1	0	0	10
骨髓抑制	0	2	1	30

[1]	Yaping Jia, Shu'e Zeng. Ultrasound and pathological characteristics of breast metaplastic carcinoma containing squamous cell carcinoma components [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 844-848.
[2]	Wei Tang, Rongquan He, Suning Huang. Application of deep learning in imaging for diagnosis, treatment and prognosis prediction of breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 323-328.
[3]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[4]	Xiaoli Yi, Shasha Hu, Yan Zhang. Impact of HER-2 low expression on response of neoadjuvant chemotherapy and prognosis in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 340-346.
[5]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[6]	Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[7]	Changsheng Lin, Jun Zhan, Xue Xiao. Genetic testing and precision molecular targeted therapy in diagnosis and treatment of epithelial ovarian caner [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 505-510.
[8]	Lu Wang, Yang Fan. Advances in endometrial cancer-related biomarker research [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 511-516.
[9]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[10]	Zhiming Li, Chenming Guo, Xiaochen Zhuang, Xueqin Hou, Junxi Gao. Comparative study of qualitative and quantitative indicators of contrast-enhanced ultrasound in early breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 639-643.
[11]	Hongbo Qu, Fang Zhu, Zhe Xu, Nan Wu, Jianhuai He, Xianming Wang. Application of subclavian lymph node dissection through intermuscular approach in locally advanced breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 510-513.
[12]	Shan Chen, Zhiqiang Hu, Yueming Zhang, Ding Tang, Meng Li, Shuai Zhao. Expression of Orai1 and Orai3 in breast cancer and their correlation with pathological indexes [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 514-517.
[13]	Xiaoyong Wei. Discussion on the focus issues of conversion therapy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 602-607.
[14]	Chenrui Wu, Rui Liao, Qiang He. Hepatic arterial infusion chemotherapy combined immunotargeted therapy for multiple metastatic hepatocellular carcinoma in a multi-disciplinary treatment model: a case report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 713-716.
[15]	Yin Wu, Zhiqin Chen, Yong Gao, Ming Quan. Progress in diagnosis and treatment of Her-2 positive colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 420-425.

Please choose a citation manager

Content to export